Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?

Marco CaminatiGabriella GuarnieriGianenrico Senna

Published in: Vaccines (2021)

The vaccination campaign against the Severe acute respiratory syndrome coronavirus 2 (Sars-Cov-2) started on 8 December 2020 in UK, after the approval of BNT162b2 by the Healthcare products Regulatory Agency (MHRA) [...].

Keyphrases

respiratory syndrome coronavirus
sars cov
healthcare
drug administration
coronavirus disease
transcription factor
cross sectional
health insurance